Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.73 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.73 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.73 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.73 |
| ▸ | ACE | P12821 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | FAP | Q12884 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9991052 | 1.00 | DPP4 (0.73) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14960664 | 1.00 | DPP4 (0.73) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL9899956 | 0.87 | DPP4 (0.89) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL9904189 | 0.86 | DPP4 (0.88) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3791188 | 0.85 | DPP4 (0.80) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1289158 | 0.85 | DPP4 (0.80) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1288978 | 0.85 | DPP4 (0.80) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL1289311 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL12257160 | 0.85 | DPP4 (0.79) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576563-B1 | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2016-05-11 | — | — | EP | disclosed |
| EP-2576563-B1 | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2016-05-11 | — | — | EP | disclosed |
| US-8765668-B2 | Methods of synthesis of β-aminobutyryl substituted compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-07-01 | — | — | US | disclosed |
| US-8765668-B2 | Methods of synthesis of β-aminobutyryl substituted compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-07-01 | — | — | US | disclosed |
| US-8765668-B2 | Methods of synthesis of β-aminobutyryl substituted compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-07-01 | — | — | US | disclosed |
| US-20130130974-A1 | NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-05-23 | — | — | US | disclosed |
| US-20130130974-A1 | NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-05-23 | — | — | US | disclosed |
| US-20130130974-A1 | NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-05-23 | — | — | US | disclosed |
| EP-2576563-A1 | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK Pharmaceuticals d.d. (SI) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151443-A1 | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151443-A1 | A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2011-12-08 | — | — | WO | disclosed |
| EP-2392575-A1 | A novel synthetic approach to ß-aminobutyryl substituted compounds | LEK Pharmaceuticals d.d. (SI) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392575-A1 | A novel synthetic approach to ß-aminobutyryl substituted compounds | LEK Pharmaceuticals d.d. (SI) | 2011-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130974-A1 | NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS | BCAT1, BCAT2, DDC | DPP4 153/4885DPP8 208/4885DPP9 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.